Skip to content

Ultrasound Cavitation Therapy for CLI

Ultrasound Cavitation for Treatment of Non-healing Ulcers in Critical Limb Ischemia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05749250
Enrollment
30
Registered
2023-03-01
Start date
2023-01-01
Completion date
2025-06-28
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Brief summary

In this study, we will explore how ultrasound exposure of ultrasound contrast agents, which produces beneficial shear-mediated bioeffects, can be used to treat patients with severe non-healing ulcers secondary to peripheral arterial disease (PAD). The primary outcome measure is whether ultrasound exposure to microbubble contrast agents in the inflow artery and at the wound site can accelerate wound healing. A secondary outcome measure is whether cavitation-related changes occur in tissue perfusion in the treated limb and wound measured by ultrasound perfusion imaging and skin flow.

Interventions

DEVICEAcoustic cavitation of ultrasound enhancing agents

Cavitation therapy

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Known history of unilateral or bilateral PAD diagnosed by reduced ankle-brachial index (\<0.9) or non-compressible vessels * Diagnosis of CLI (Rutherford class IV-VI), and a non-healing ischemic ulcer defined as no change in the prior 3 months.

Exclusion criteria

* Major medical illness other than PAD affecting the limb (muscle disease, blood diseases that influence flow or rheology, severe heart failure \[NYHA class IV\]). * Pregnant or lactating females * Hypersensitivity to any ultrasound contrast agent or to polyethylene glycol (PEG, macrogol). * Hemodynamic instability (hypotension with systolic BP \<90 mm Hg, need for vasopressors). * Expected amputation or revascularization procedure within the ensuing 1 month.

Design outcomes

Primary

MeasureTime frameDescription
Wound dimensions18 daysArea of non-healing ulcer

Secondary

MeasureTime frameDescription
Wound granulation18 daysArea of granulation tissue of the ulcer
Tissue perfusion18 daysLaser speckle perfusion imaging

Countries

United States

Contacts

Primary ContactJonathan Lindner, MD
jlindner@virginia.edu434 297-9442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026